title: Thrombomodulin overexpression to limit neointima formation.
abstract: BACKGROUND-These studies were initiated to confirm that high-level thrombomodulin overexpression is sufficient to limit neointima formation after mechanical overdilation injury. METHODS AND RESULTS-An adenoviral construct expressing thrombomodulin (Adv/RSV-THM) was created and functionally characterized in vitro and in vivo. The impact of local overexpression of thrombomodulin on neointima formation 28 days after mechanical overdilation injury was evaluated. New Zealand White rabbit common femoral arteries were treated with buffer, viral control, or Adv/RSV-THM and subjected to mechanical overdilation injury. The treated vessels (n=4 per treatment) were harvested after 28 days and evaluated to determine intima-to-media (I/M) ratios. Additional experiments were performed to determine early (7-day) changes in extracellular elastin and collagen content; local macrophage, T-cell, and neutrophil infiltration; and local thrombus formation as potential contributors to the observed impact on 28-day neointima formation. The construct significantly decreased neointima formation after mechanical dilation injury in this model. By histological analysis, buffer controls exhibited mean I/M ratios of 0.76+/-0.06%, whereas viral controls reached 0.77+/-0.08%; in contrast, Adv/RSV-THM reduced I/M ratios to 0.47+/-0.06%. Local inflammatory infiltrate decreased in the Adv/RSV-THM group relative to controls, whereas matrix remained relatively preserved. Rates of early thrombus formation also decreased in Adv/RSV-THM animals. CONCLUSIONS-This construct thus offers a viable technique for promoting a locally neointima-resistant small-caliber artery via decreased thrombus bulk, normal matrix preservation, and decreased local inflammation without the inflammatory damage that has limited many other adenoviral applications.
authors.affiliation: Department of Cell Biology, Baylor College of Medicine, Houston, Tex.
authors.forename: J M
authors.initials: JM
authors.lastname: Waugh
authors.forename: J
authors.initials: J
authors.lastname: Li-Hawkins
authors.forename: E
authors.initials: E
authors.lastname: Yuksel
authors.forename: M D
authors.initials: MD
authors.lastname: Kuo
authors.forename: P N
authors.initials: PN
authors.lastname: Cifra
authors.forename: P R
authors.initials: PR
authors.lastname: Hilfiker
authors.forename: R
authors.initials: R
authors.lastname: Geske
authors.forename: M
authors.initials: M
authors.lastname: Chawla
authors.forename: J
authors.initials: J
authors.lastname: Thomas
authors.forename: S M
authors.initials: SM
authors.lastname: Shenaq
authors.forename: M D
authors.initials: MD
authors.lastname: Dake
authors.forename: S L
authors.initials: SL
authors.lastname: Woo
mesh_terms: D000818:Animals; D002404:Catheterization / Q000009:adverse effects; D005109:Extracellular Matrix / Q000378:metabolism; D005263:Femoral Artery / Q000293:injuries / Q000378:metabolism / Q000473:pathology; D018014:Gene Transfer Techniques; D011817:Rabbits; D018180:Thrombomodulin / Q000235:genetics / Q000378:metabolism*; D013927:Thrombosis / Q000209:etiology; D017539:Tunica Intima / Q000473:pathology / Q000503:physiopathology*; D017540:Tunica Media / Q000473:pathology; D014657:Vasculitis / Q000209:etiology; D014947:Wounds and Injuries / Q000503:physiopathology
chemical_list: D018180:Thrombomodulin